Clinical drug resistance: the role of factors other than P-glycoprotein

The American Journal of Medicine
S B Kaye

Abstract

Clinical drug resistance is a major obstacle to successful chemotherapy for cancer. When it occurs, resistance to a wide range of agents is noted. This clinical observation should not be confused with so-called "multidrug resistance," which is a laboratory-based phenomenon, whereby cross-resistance in experimental models to structurally unrelated compounds is seen and is due to increased expression of P-glycoprotein (PGP). In the majority of cases of clinical drug resistance in solid tumors it is likely that other factors will play a major role. These other factors can be defined as pharmacologic or cellular. Pharmacologic factors are those that prevent an adequate degree of tumor cell exposure and include considerations of dose and schedule of drug, and also of drug metabolism, which may relate to concomitant medication and to genetic variations. Clinical maneuvers to circumvent drug resistance by increasing dose are so far of unproven value. Cellular factors are those that apply at the tumor cell itself, and it is probable that multiple mechanisms exist. These include considerations of drug uptake, activation/inactivation, and changes in target enzymes and in DNA repair processes. After DNA damage has occurred, a key determin...Continue Reading

References

Nov 11, 1976·Biochimica Et Biophysica Acta·R L Juliano, V Ling
Aug 21, 1991·Journal of the National Cancer Institute·C SessaM D'Incalci
Jan 1, 1989·Pharmacology & Therapeutics·E S Vesell
Oct 1, 1980·The American Journal of Medicine·E Frei, G P Canellos
Dec 1, 1980·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J H GoldieS Dedhar
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S B Kaye

❮ Previous
Next ❯

Citations

Feb 14, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J WalkerR Callaghan
Feb 28, 2006·Investigational New Drugs·Venugopal MarasanapalleBhaskara R Jasti
Nov 6, 2002·Journal of Experimental Therapeutics & Oncology·Andrew G BosanquetPhilip B Bell
Nov 26, 1998·The Journal of Biological Chemistry·Y LavieM Liscovitch
Dec 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alejandro D RicartMace L Rothenberg
Sep 12, 2001·Advanced Drug Delivery Reviews·Y LavieM Liscovitch
Nov 21, 2000·Trends in Biochemical Sciences·M Liscovitch, Y Lavie
Mar 16, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S Cara, I F Tannock
Apr 30, 1998·Hematology/oncology Clinics of North America·R J ArceciJ Pritchard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis